ad 452
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2005 (NCT00141934)
Timeline
Indications
Mechanism of action
- SARS-CoV-2Immunity, passive
SARS-CoV-2 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ad 452
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00931697 | Phase 1 | Jun 1, 2009 | Medicines for Malaria Venture, Treague Ltd |
| NCT00141934 | Phase 2 | Aug 1, 2005 | Sosei |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Medicines for Malaria Venture | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Sosei | For profit | 1 | 1 | 1 | 2005 |
| Treague Ltd | For profit | 1 | 1 | 1 | 2009 |
3 organizations
Page 1 / 1